Bexitrol F

Pack	Price	Details
120 metered doses	৳	120 metered doses: ৳ 595.00

Inhaler:

• Adults and adolescents 12 years and older: 2 puffs of 25 µg Salmeterol and 50 µg Fluticasone twice daily or 2 puffs of 25 µg+125 µg twice daily or 2 puffs of 25 µg+250 µg twice daily.
• Children (4-12 years): 2 puffs of 25 µg+50 µg twice daily.

Inhalation capsule for asthma:

• Adult and Adolescent (12 Years and Older): 50 µg+100 µg or 50 µg+250 µg twice daily (morning and evening, approximately 12 hours apart). 
• The recommended starting dosages for 50 µg+100 µg & 50 µg+250 µg for patients aged 12 years and older are based upon patients asthma severity. The maximum recommended dosage is 50 µg+500 µg twice daily.
• Pediatric Patients (4 to 11 Years): For patients with asthma who are not controlled on an inhaled corticosteroid, the dosage is 50 µg+100 µg twice daily (morning and evening, approximately 12 hours apart).

Inhalation capsule for COPD: 50 µg+250 µg twice daily (morning and evening, approximately 12 hours apart). Rinsing the mouth after each inhalation is advised.

Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available for use of this in patients with hepatic impairment.

Using the inhaler: This is a patient friendly, ready to use and easy to grip device. Use as per instructions for use.

As Bexitrol F contains Salmeterol and Fluticasone Propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds. Adverse events, which have been associated with Salmeterol or Fluticasone Propionate, are given below.

Salmeterol: The pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. Cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. There have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. There have been reports of oropharyngeal irritation. There have been rare reports of muscle cramps.

Fluticasone propionate: Hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. Cutaneous hypersensitivity reactions have been reported. Rare cases of facial and oropharyngeal oedema have been reported. Both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of Salmeterol/ Fluticasone Propionate Inhaler.

Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:

• Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
• Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

Salmeterol Xinafoate is a selective, long-acting beta-2 agonist used in the treatment of asthma and other forms of diffuse airway obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systematic effects at usual dose. Salmeterol protects against symptoms, Fluticasone Propionate improves lung function and prevents exacerbations of the condition. This preparation can offer a more convenient regime for patients on concurrent β-agonist and inhaled corticosteroid therapy. The respective mechanisms of action of both drugs are discussed below:

Salmeterol: Salmeterol is a selective long-acting (12-hour) beta-2-adrenoceptor agonist with a long side chain that binds to the exo-site of the receptor.

Fluticasone Propionate: Fluticasone Propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, without the adverse effects observed when corticosteroids are administered systemically.

Use in asthma patients: This inhalation capsule should not be initiated in patients during an exacerbation, or if they have unstable or acutely deteriorating asthma. This inhalation capsule is not for relief of acute symptoms for which a fast and short-acting bronchodilator (e.g. salbutamol) is required. Patients should be advised to have their relief medication available at all times.

Asthma-related adverse events: Serious asthma-related adverse events and exacerbations may occur during treatment with this inhalation capsule. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of this inhalation capsule.

Paradoxical Bronchospasm: As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast and short-acting inhaled bronchodilator. This inhalation capsule should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache have been reported, but tend to be transient and to reduce with regular therapy.

Use in COPD patients: There was an increased reporting of pneumonia in studies of patients with COPD receiving salmeterol/fluticasone inhaler. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbation frequently overlap.

Corticosteroids: This inhalation capsule contains an inhaled corticosteroid (fluticasone propionate). Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation and (very rarely) behavioral disturbances in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Therefore, it is important, that the patient is reviewed regularly and the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.

Long-acting selective β-adrenoceptor stimulants, Respiratory corticosteroids

Leave a review (no account needed)

Your rating *

Post review Sign in with Google to skip the form fields.